Can ALT maintain profitability with current cost trends?

**Altimmune's profitability is currently under pressure due to high operating costs and negative net margins.** The company's stock, ALT, reflects this challenge with a negative net margin of -475295% and an operating margin of -475535% as of December 31, 2024. Despite a gross margin of 100%, the substantial operating and net losses indicate significant financial strain.

|code|Ticker|Name|Date|Gross Profit Margin|Operating Profit Margin|Net Profit Margin|market_code|
|---|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q1|100|-487639.99999999994|-487880|185|
|ALT|ALT.O|Altimmune|2024 Q2|100|-489460.00000000006|-490340|185|
|ALT|ALT.O|Altimmune|2024 Q3|100|-478726.6666666666|-479193.3333|185|
|ALT|ALT.O|Altimmune|2024 Q4|100|-475535.00000000006|-475295|185|

**The situation is further highlighted by the company's financial ratios.** With a P/E (Price/ Earnings) ratio of -4.34 as of May 7, 2025, ALT suggests that the market may not be confident in future earnings potential. Additionally, an RSI (Relative Strength Index) of 56.76 indicates the stock is neither overbought nor oversold, which does not provide a clear signal for future price movements.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|2024 Q1|-76.19047619047619|5000|185|
|ALT|ALT.O|Altimmune|2024 Q2|-16.666666666666664|5000|185|
|ALT|ALT.O|Altimmune|2024 Q3|-98.61878453038673|5000|185|
|ALT|ALT.O|Altimmune|2024 Q4|-86.48648648648648|5000|185|

|code|Ticker|Name|Date|RSI|market_code|
|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20250507|56.7577|185|

|code|Ticker|Name|Date|P/E(TTM)|market_code|
|---|---|---|---|---|---|
|ALT|ALT.O|Altimmune|20240507|-5.55649|185|
|ALT|ALT.O|Altimmune|20240508|-5.472416|185|
|ALT|ALT.O|Altimmune|20240509|-5.900427|185|
|ALT|ALT.O|Altimmune|20240510|-5.518275|185|
|ALT|ALT.O|Altimmune|20240513|-5.63292|185|
|ALT|ALT.O|Altimmune|20240514|-5.976857|185|
|ALT|ALT.O|Altimmune|20240515|-6.779376|185|
|ALT|ALT.O|Altimmune|20240516|-6.802305|185|
|ALT|ALT.O|Altimmune|20240517|-6.122075|185|
|ALT|ALT.O|Altimmune|20240520|-6.145004|185|

**In conclusion, Altimmune faces a critical period in maintaining profitability.** The company's focus on developing novel therapies for liver and cardiometabolic diseases, as evidenced by its presentations at the EASL International Liver Congress™ 2025, highlights its commitment to innovation. However, the immediate profitability concerns necessitate careful financial management and potentially, strategic partnerships or funding initiatives to bridge the gap to profitability.